Compare Diageo plc (DEO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Illumina, Inc. — how do they compare? Diageo plc trades at $82.67 (market cap $45.41B), while Illumina, Inc. trades at $189.79 (market cap $28.93B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays a 4.02% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DEO | ILMN | |
|---|---|---|
Market Cap | $45.41B | $28.93B |
Sector | Technology | Health |
52-Week High | $115.33 | $194.33 |
52-Week Low | $72.47 | $91.00 |
Enterprise Value | $66.23B | $30.32B |
Dividend Yield | 4.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $82.50, up 0.57% today, with a bullish technical trend and strong profitability metrics including a 12.19% net margin and 22.29% ROE. Recent earnings show mixed results with a Q4 2025 beat but a Q2 2025 miss, while analyst sentiment is positive with 49% buy ratings. The stock faces headwinds from weak U.S. spirits demand and promotional pressures, as noted in recent Deutsche Bank and UBS reports from July 2026.
The outlook hinges on management's strategy reset in August 2026 to address U.S. volume declines and margin pressures. Investment appeal lies in its discounted valuation relative to historical multiples and dividend yield, but risks include sustained consumer moderation trends and execution challenges in key markets.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
